Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trial

Background Despite the relative success of immuno-modulatory disease-modifying therapy in relapsing remitting multiple sclerosis, progressive worsening of disability remains a major problem, particularly for those with secondary progressive multiple sclerosis. Various underlying mechanisms are likel...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Thomas Williams, James Blackstone, Nevin John, Marie Braisher, Floriana De Angelis, Alessa Bianchi, Alberto Calvi, Anisha Doshi, Sean Apap Mangion, Charles Wade, Ekaterina Bordea, Rachel Merry, Gil Barton, Dawn Lyle, Elisabeth Jarman, Don Mahad, Abdullah Shehu, Tarunya Arun, Gavin McDonnell, Ruth Geraldes, Matthew Craner, Charles Hillier, Jeban Ganesalingam, Leonora Fisniku, Jeremy Hobart, Cord Spilker, Neil P Robertson, Seema Kalra, Stefano Pluchino, Sreedharan Harikrishnan, Miriam Mattoscio, Timothy Harrower, Carolyn Young, Martin Lee, Suresh Kumar Chhetri, Fayyaz Ahmed, David Rog, Eli Silber, Paul Gallagher, Martin Duddy, Agne Straukiene, Richard Nicholas, Claire Rice, Susan Tebbs, Annie Hawton, Rachael Hunter, Gavin Giovannoni, Olga Ciccarelli, Judy Beveridge, Stuart Nixon, Alan J Thompson, John Greenwood, Owen Pearson, Nikos Evangelou, Basil Sharrack, Ian Galea, Sue Pavitt, Siddharthan Chandran, Helen L Ford, Jennifer M Nicholas, Jeremy Chataway
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	NIHR Journals Library 2026-06-01
Ráidu:	Health Technology Assessment
Fáttát:	multiple sclerosis progressive multiple sclerosis secondary progressive multiple sclerosis randomised controlled trial simvastatin
Liŋkkat:	https://doi.org/10.3310/GJJC5820
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!